BACKGROUND: Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells. Approximately half of all adult AML patients have a normal karyotype (NK-AML) and an intermediate risk prognosis. AIMS: To determine the incidence and prognostic significance of NPM1 and FLT3-ITD mutations in a population of patients with NK-AML. METHODS: FLT3-ITD and NPM1 mutation status was retrospectively sought in presentation samples from 44 NK-AML patients. RESULTS: FLT3-ITD and NPM1 mutations were detected in 45.5 and 54.5% of patients, respectively, allowing stratification according to genotype. CONCLUSIONS: FLT3-ITD and NPM1 mutation status can be defined in NK-AML. Prospective screening for these mutations is advocated in all NK-AML patients, as the genotype is of clinical importance when considering treatment options including stem cell transplantation.
BACKGROUND: Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells. Approximately half of all adult AMLpatients have a normal karyotype (NK-AML) and an intermediate risk prognosis. AIMS: To determine the incidence and prognostic significance of NPM1 and FLT3-ITD mutations in a population of patients with NK-AML. METHODS:FLT3-ITD and NPM1 mutation status was retrospectively sought in presentation samples from 44 NK-AMLpatients. RESULTS:FLT3-ITD and NPM1 mutations were detected in 45.5 and 54.5% of patients, respectively, allowing stratification according to genotype. CONCLUSIONS:FLT3-ITD and NPM1 mutation status can be defined in NK-AML. Prospective screening for these mutations is advocated in all NK-AMLpatients, as the genotype is of clinical importance when considering treatment options including stem cell transplantation.
Authors: H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda Journal: Blood Date: 1999-05-01 Impact factor: 22.113
Authors: Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner Journal: Blood Date: 2005-07-28 Impact factor: 22.113
Authors: Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch Journal: Blood Date: 2007-10-23 Impact factor: 22.113
Authors: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Friederike Schneider; Eva Hoster; Michael Unterhalt; Stephanie Schneider; Annika Dufour; Tobias Benthaus; Gudrun Mellert; Evelin Zellmeier; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske; Jan Braess; Susanne Fritsch; Achim Heinecke; Maria C Sauerland; Wolfgang E Berdel; Thomas Buechner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann Journal: Blood Date: 2009-03-11 Impact factor: 22.113
Authors: Suruchi Pacharne; Oliver M Dovey; Jonathan L Cooper; Muxin Gu; Mathias J Friedrich; Sandeep S Rajan; Maxim Barenboim; Grace Collord; M S Vijayabaskar; Hannes Ponstingl; Etienne De Braekeleer; Ruben Bautista; Milena Mazan; Roland Rad; Konstantinos Tzelepis; Penny Wright; Malgorzata Gozdecka; George S Vassiliou Journal: Blood Adv Date: 2021-05-11